Implementing the 'OA pyramid of care'August 17, 2023As we know, a client may need to hear about your OA concerns several times before it registers, and the best time to start the conversation is when your patient is healthy, before the disease process may have begun.
SPONSORED CONTENTLife Gets Busy, Stay ON POINT With Cytopoint®Simplify your approach to allergic pruritus with Cytopoint. Help maintain control of allergic itch when schedules get hectic for both veterinarians and pet owners alike. + Learn more
Early interventions aid in juvenile fracturesJune 13, 2023Orthopedic injuries in our juvenile patients can be challenging and rewarding all at the same time. Puppies and kittens are resilient on so many levels. Their energetic and explosive antics can sometimes lead to injury, however, seemingly minor trauma can lead to serious injury.
Managing osteoarthritis with natural neuromodulationJune 5, 2023You may have heard a lot lately about monoclonal antibodies (mABs) for osteoarthritis (OA) pain. These agents inhibit a nerve growth factor (NGF), a molecule located in the peripheral nervous system that can contribute to neurogenic inflammation.
Canine OA injectable gets green lightMay 5, 2023Dogs afflicted with osteoarthritis (OA) pain can soon benefit from a novel treatment.
Brain Teaser: Can you solve this puzzle?February 1, 2023Test your veterinary knowledge with our monthly challenge.
VPN Plus+ ExclusiveQuestions about anti-nerve growth factor drugsDecember 1, 2022When the guidelines first showed up, most veterinarians couldn’t even access antiNGF mAB drugs. The feline version, frunevetmab, received Food and Drug Administration (FDA) approval on January 13, 2022, but it remained unavailable to most veterinarians well into the summer. We still do not know when, or if, the canine version will receive a green light from the FDA.
Why diagnosing OA pain in cats is not easyApril 8, 2022Osteoarthritis (OA) is among the most common age-related conditions in cats.
Feline OA injectable gets green lightJanuary 28, 2022Zoetis’ Solensia treatment, containing the active ingredient frunevetmab, has been approved by the U.S. Food and Drug Administration.
Injectable therapy for canine pain managementSeptember 23, 2021Osteoarthritis (OA), also known as degenerative joint disease (DJD), is the No. 1 cause of chronic pain in dogs in the United States.
How best to manage canine osteoarthritis with nutritionJuly 9, 2021Mild and moderate osteoarthritis can be managed effectively using nutritional supplements, delaying the need for treatment with NSAIDs.
